First Steps toward Personalized Therapies for ABCA3 Deficiency
- PMID: 35077664
- PMCID: PMC8990116
- DOI: 10.1165/rcmb.2021-0405ED
First Steps toward Personalized Therapies for ABCA3 Deficiency
Comment on
-
High-Content Screening Identifies Cyclosporin A as a Novel ABCA3-Specific Molecular Corrector.Am J Respir Cell Mol Biol. 2022 Apr;66(4):382-390. doi: 10.1165/rcmb.2021-0223OC. Am J Respir Cell Mol Biol. 2022. PMID: 34936540
References
-
- Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med . 2004;350:1296–1303. - PubMed
-
- Kröner C, Wittmann T, Reu S, Teusch V, Klemme M, Rauch D, et al. Lung disease caused by ABCA3 mutations. Thorax . 2017;72:213–220. - PubMed
-
- Klay D, Platenburg MGJP, van Rijswijk RHNAJ, Grutters JC, van Moorsel CHM. ABCA3 mutations in adult pulmonary fibrosis patients: a case series and review of literature. Curr Opin Pulm Med . 2020;26:293–301. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
